We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
-14.55%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$500M
AUM Growth
+$2.67M
(+0.54%)
Cap. Flow
+$135M
Cap. Flow
% of AUM
26.95%
Top 10 Holdings %
Top 10 Hldgs %
57.76%
Holding
60
New
31
Increased
5
Reduced
6
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$36.4M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$24.1M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$15.3M |
| 4 |
ISPO
Inspirato
ISPO
|
+$15M |
| 5 |
ALBO
Albireo Pharma Inc
ALBO
|
+$13.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$29.7M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$21.9M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$18.2M |
| 4 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$17.2M |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$7.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.05% |
| 2 | Consumer Discretionary | 1.95% |
| 3 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sky Harbour Group Warrants
SKYH.WS
$21.4M
| $694K | 0.14% |
+459,611
| New | +$471K |
|
52
Q32 Bio
QTTB
$464M
| $653K | 0.13% |
+11,939
| New | +$742K |
|
53
TScan Therapeutics
TCRX
$52M
| $560K | 0.11% |
+200,000
| New | +$865K |
|
54
CytomX Therapeutics
CTMX
$754M
| – | – |
-152,345
| Closed | -$660K |
|
55
Relmada Therapeutics
RLMD
$527M
| – | – |
-59,122
| Closed | -$1.33M |
|
|
ONC
56
BeOne Medicines Ltd
ONC
$39.4B
| – | – |
-20,000
| Closed | -$5.42M |
|
|
CALT
57
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| – | – |
-100,000
| Closed | -$2.48M |
|
|
CCXI
58
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-500,000
| Closed | -$18.2M |
|
|
RDUS
59
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-763,888
| Closed | -$5.29M |
|
|
ODT
60
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| – | – |
-12,767,435
| Closed | -$17.2M |
|
Similar funds
HA
NIM
RMCM
FC
SC
CAM
BC
FFH
Tang Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Tang Capital Management held 60 positions worth $500M, up 0.54% from $497M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Tang Capital Management deployed $135M of net new capital in Q1 2022, opening 31 new positions and adding to 5 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 700,000 shares worth $42.8M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Heron Therapeutics, an estimated $29.7M trimmed.
- Tang Capital Management's largest Q1 2022 buy was Intra-Cellular Therapies Inc.: 700,000 shares worth $42.8M.
- Tang Capital Management added most to Altimmune in Q1 2022, an estimated $7.17M increase.
- Tang Capital Management's biggest Q1 2022 reduction was Heron Therapeutics, cutting an estimated $29.7M.
- Tang Capital Management fully exited ChemoCentryx, Inc. in Q1 2022, selling an estimated $18.2M.
- Tang Capital Management's ten largest holdings make up 58% of its $500M portfolio in Q1 2022.
- Tang Capital Management opened 31 new positions and closed 7 in Q1 2022.
- Tang Capital Management's portfolio value rose 0.54% quarter-over-quarter to $500M.
Based on Tang Capital Management's 13F filing for Q1 2022, filed 16 May 2022.